BARDA, J&J partner against chemical, biological and nuclear threats

HHS’s Biomedical Advanced Research and Development Authority partnered with Johnson & Johnson (NYSE:JNJ) to develop products to fight chemical, biological, radiation and nuclear threats, infectious diseases and antimicrobial resistant infections.

BARDA will initially provide more than $28 million over two years, and may provide up to $200 million over six years. The first compound under the project will target acute radiation syndrome and chemical threats. HHS said the product enhances survival and has shown beneficial effects on blood cells, which can be injured by radiation...